Drugs / rolofylline
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00729222 | Nov 2008 → Mar 2009 | heart failure | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00159614 | Sep 2005 → ? | congestive heart failure, impaired renal function disease | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00159627 | Aug 2004 → ? | congestive heart failure | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 33 trials · 2 missed | ||||||
| Phase 3 | NCT00443690 | Aug 2007 → Jan 2009 | congestive heart failure | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00354458 | Oct 2006 → Jul 2009 | congestive heart failure | Merck & Co., Inc. | Completed | Missed primary |
| Phase 3 | NCT00328692 | Aug 2006 → Jul 2009 | congestive heart failure | Merck & Co., Inc. | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rolofylline | “Subjects then received furosemide administered intravenously along with the AA1R antagonist, KW-3902 (rolofylline), or placebo.” PMID 17923351 ↗ Oct 2007 |
| Known as | KW-3902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00159627 ↗ |
| Known as | MK-7418 | ChEMBL registry synonym — accepted as the source's own label CHEMBL52333 ↗ |
| Known as | Rolofyllina | ChEMBL registry synonym — accepted as the source's own label CHEMBL52333 ↗ |
| Action | Inhibit | “rolofylline, an adenosine A1-receptor antagonist” PMID 20925544 ↗ Oct 20101“Adenosine A1 receptor antagonist” CHEMBL52333 ↗ |
| Modality | Small molecule | — CHEMBL52333 ↗ |
| Route | Intravenous | “KW-3902IV” NCT00159627 ↗ |
| Target | ADORA1 | “Adenosine A1 receptor antagonist” CHEMBL52333 ↗ |